<DOC>
	<DOCNO>NCT01555658</DOCNO>
	<brief_summary>Background : Randomized trial show improve outcome among acute coronary syndrome ( ACS ) patient treat Bivalirudin1 . Optimal antithrombotic treatment patient undergo percutaneous coronary intervention ( PCI ) crucial balance risk post-PCI bleeding versus ischemic complications2 . Bivalirudin , direct thrombin inhibitor extensively investigate intra-procedural antithrombotic therapy patient stable angina , Non ST-segment elevation acute coronary syndrome ( NSTE-ACS ) , ST-segment elevation myocardial infarction ( STEMI ) . Bivalirudin , use without glycoprotein IIb/IIIa inhibitor ( GPI ) PCI find superior Unfractionated heparin ( UFH ) without GPI reduce 30-day bleeding complication without significant increase rate ischemic events3-5 . Moreover , otherwise successful PCI , increase cardiac biomarkers show occur 5 % 30 % patients6 . Recent study focus attention onthe reduction infarct size incidence periprocedural ( type IVa ) myocardial infarction ( PMI ) elective PCI7-8 . Therefore , perform single-center , prospective randomize study ass Bivalirudin versus UFHis effective prevent elevation biomarkers MI coronary stent implantation patient already treat aspirin clopidogrel , anatomically complex lesion . Objective : ass safety efficacy routine usage Bivalirudin v UFH patient coronary artery disease ( CAD ) , stent implantation coronary long lesion , avoid periprocedural myocardial necrosis . Setting : Single-center , spontaneous , prospective , randomize 1:1 study Bivalirudin infusion v UFH set CAD , PCI stenting incoronary long lesion . Comparison : Bivalirudin v UFH , prevent elevation biomarkers MI coronary stent implantation patient already treat aspirin clopidogrel , anatomically complex lesion . Population : Patients diffuse CAD undergo percutaneous treatment native coronary vessel plan implantation stent overlap total stent length &gt; 33 mm long coronary lesion vessel reference vessel diameter 2.25-4.0 mm . Assessment Following procedure , blood sample CK , CK-MB Troponin collect 6,12 24 h post PCI . CK-MB value consider abnormal elevate upper limit normal ( ULN ) . This set 6 mg/L local laboratory . If first blood sample show CK-MB level ≥18 mg/L ( ≥3 time upper normal limit ) , second blood sample would draw every 8 h later downward trend observe . For patient two blood sample draw , peak CK-MB level use analysis . End-points : The primary end-point study incidence periprocedural myonecrosis define peak post-procedural CK-MB elevation &gt; 1 time upper limit normal ( ULN ) alone associate chest pain ST-segment T-wave abnormality , patient undergo non-urgent PCI . Secondary end-points rate MACCE ( major adverse cerebro-cardiovascular event , ie composite death , myocardial infarction [ define accord Academic Research Consortium statement ] , target vessel revascularization stroke ) , rate major bleeding ( Bleeding Academic Consortium [ BARC ] 3-5 ) , minor bleeding ( BARC 2 ) , rate NACE ( net adverse clinical event , ie composite MACCE major bleeding ) 30 day , 6 12 month follow-up . Adverse event determine telephone interview and/or medical record review . Clinical follow-up : telephone-based interview office-based direct visit perform 1 , 6 12 month , respectively , end-point adjudication . Sample size statistical analysis : Given expected rate abnormal post-procedural peak CK-MB &gt; 1 x ULM 48 % ( base result INSTANT trial ) control group 29 % experimental group ( thus 40 % relative risk reduction ) , aim 0.05 alpha 0.80 power , total 204 patient need enrol ( 102 patient per group ) .</brief_summary>
	<brief_title>Bivalirudin Plus Stenting Long Lesion Avoid Periprocedural Myocardial Necrosis Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Clinical Inclusion Criteria Candidates study must meet following criterion : Male female able understand sign witness informed consent Age ≥ 18 yo Patients stable ( CCS 14 ) unstable angina pectoris ( recent anginal episode occur &gt; 48 hour index procedure ) document silent ischemia Ongoing recent episode ( &lt; 48 hour ) unstable coronary artery disease ( include nonSTelevation acute coronary syndrome ) Stable Hemodynamic condition ( systolic BP &gt; 100 HR &gt; 40 &lt; 100 ) . No clinical ECG change suggestive ongoing acute recent ( &lt; 48 hour ) myocardial infarction . Angiographic inclusion criterion Angiographic evidence de novo lesion &gt; 50 % require implantation two stent overlap total stent length &gt; 33 mm reference vessel diameter 2.5 4.0 mm ( visual estimation ) one coronary vessel . Multiple lesion vessel include least one lesion require implantation two stent overlap total stent length &gt; 33 mm . The definition multivessel disease require intention treat least two lesion ( least one characteristic report ) two different major epicardial segment . For example , presence lesion leave anterior descend artery obtuse marginal presence lesion right posterolateral branch diagonal branch qualify multivessel . The presence lesion leave anterior descend artery diagonal branch qualify multivessel . Bifurcation lesions ostial lesion include , least two stent overlap total stent length &gt; 33 mm implant branch . When treat diffuse lesion vessel , overlap stenting recommend high pressure ( &gt; 14 atm postdilation ) overlap zone . There maximum stent length treat one coronary vessel . Clinical Exclusion criterion Female sex childbearing potential Age &lt; 18 year Serum creatinine &gt; 2.5 mg/dl creatinine clearance &lt; 40mL/min Ongoing serious bleed bleed diathesis Previous stroke last 6 month Major surgery within previous 6 week Platelet count &lt; 100,000 per mm3 Ejection Fraction 30 % STEMIpatients ' treated primaryPCI , rescuePCI facilitatedPCI thrombolysis therapy . Patients treat Glycoprotein IIb/IIIa inhibitor ACS The patient know hypersensitivity contraindication aspirin , heparin , clopidogrel , sensitivity contrast adequately premedicated . Hemodynamic instability ( systolic blood pressure &lt; 100 mm Hg ; heart rate &lt; 40 bpm &gt; 100 bpm ; complex ventricular arrhythmia ; AV block ) require balloon counterpulsation inotropic support . The patient simultaneously participate another device drug study . Patient must complete followup phase previous study least 30 day prior enrolment study . Positive clinical history intracranial neoplasia , AV malformation , aneurysm . INR ≥ 2.0 prothrombin time 1.2 time upper limit normality Clinically manifest reduce liver function Programmed surgery within six month Angiographic exclusion criterion Vessel size &lt; 2.25 mm &gt; 5 mm ( visual estimation ) . Previous implantation baremetal drugeluting stent target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Long Lesions</keyword>
	<keyword>Stent Implantation</keyword>
</DOC>